Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann, +41

The Lancet Oncology

Sorafenib Versus PlaceboHematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematology +7

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Christoph Röllig, Michael Krämer, Christoph Schliemann, +39

Blood

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos, +273

Clinical Lymphoma Myeloma & Leukemia

Elevated Serum Thrombopoietin and Interleukin-6 Concentrations in Thrombocytosis Associated with Inflammatory Bowel Disease

Frank Heits, Maren Stahl, D Ludwig, +2

Journal of Interferon & Cytokine Research

Serum ThrombopoietinImmunologyImmune RegulationPathologyInterleukin-6 Concentrations +15

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

Kai Hübel, Maximilian M. Fresen, Hans Salwender, +24

Bone Marrow Transplantation

MedicinePharmacologyPoor MobilizersPharmacotherapyMetronomic Chemotherapy +3

Systemic Infection of an Immunocompromised Patient with <i>Methylobacterium zatmanii</i>

Britt Hornei, Edeltraud Lüneberg, H. Schmidt-Rotte, +4

Journal of Clinical Microbiology

Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy‐induced thrombocytopenia

Frank Heits, Dörthe M. Katschinski, U. Wilmsen, +2

European Journal Of Haematology

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

Christoph Röllig, Michael Krämer, Maria Gabrecht, +25

Annals of Oncology

Hematological MalignancyElderly PatientsMedicineAcute Myeloid LeukemiaIntermediate-dose Cytarabine +6

The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann, +38

Blood

Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients

Frank Heits, Dörthe M. Katschinski, G. Wiedemann, +2

International Journal of Oncology

Tumor BiologyAngiogenesisMedicineTumor GrowthSerum Vegf +13